Alveron Pharma has successfully completed its first-in-human trial of OKL-1111, a new drug for the rapid treatment of intracranial haemorrhage associated with the use of anticoagulants or platelet inhibitors. The study was conducted at Hammersmith Medicines Research in London. OKL-1111 was well-tolerated in the trial with healthy human volunteers and showed no more adverse events above those in the placebo groups. Volunteers also received an anticoagulant and a pharmacodynamic effect was observed with OKL-1111 administration. In the prior non-clinical program, the drug reduced bleeding in a…
Press release
Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB
Edinburgh and Cambridge, UK, 29 September 2023 - Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB).
Macomics’ operations are located in Edinburgh and…
Cambridge, UK – 27 September 2023 – Eagle Genomics (“Eagle”) is pleased to announce it has raised additional financing of £3 million (USD $4 million) with continued participation from existing investors Environmental Technologies Fund, abrdn plc, and a consortium of investors headed by Granpool Innovative Investments, to further deploy its pioneering software platform that enables corporate customers to explore and monetize on microbiome-related research. The current funding brings Eagle’s total capital raising to over £20 million (USD $25 million) over the last 12 months.
Together with this…
Reflects evolution of the Company from research and development towards scale-up and commercialization
Cambridge, UK, 26 September 2023– EVONETIX LTD (‘Evonetix’), the Company developing semiconductor scale technology to improve access to gene synthesis, today announces the introduction of new branding to align with its vision to ‘Redefine possible’ through the development and commercialization of its benchtop semiconductor gene synthesis platform. The rebrand follows a period of significant milestones, including external evaluation of Evonetix’s chip-synthesized DNA.
Evonetix’s gene…
We are delighted to announce that our latest whitepaper, in collaboration with Back Bay Life Science Advisors: 'Microbiome Medicinal Products: Concept to Commercial', is now available to read and download.
This whitepaper delves into the dynamic field of live biotherapeutic drug development, which over the last decade has emerged from an area of intriguing pre-clinical and clinical data to a space with multiple licensed medicines. This paper offers a comprehensive analysis of the current regulatory landscape, investment trends, and developmental strides in areas extending beyond gut…
Press release
Macomics Launches Super Triathlon Challenge to Raise Funds for Prof. Jeffrey Pollard Memorial Fund
Edinburgh and Cambridge, UK, 25 October 2023 – Macomics Ltd, a leader in macrophage drug discovery, is delighted to announce that it has launched the Macomics Hyper-Triathlon Challenge, in honour of its co-founder Prof. Jeffrey Pollard, who passed away earlier this year, to raise funds for the newly established Jeff Pollard’s memorial fund.
The new charitable fund, managed by the University of Edinburgh where Prof. Pollard was Director of the MRC Centre for Reproductive Health,…
Sygnature Discovery and UBE Corporation have begun a collaboration on a Hit-to-Lead program to identify SHP2 degraders.
SHP2 is a tyrosine-specific phosphatase implicated in human cancers and the objective is to develop potent bifunctional compounds with excellent ADME and PK properties for efficient degradation of SHP2.
Through the collaboration, the teams have discovered unique hit compounds (profile: single-digit nM DC50 and approximately 100% Dmax) utilizing Sygnature Discovery’s innovative proprietary CHARMED technology platform.
The CHARMED platform was developed by Sygnature…
Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength.
The "Most Influential List of China's Pharmaceutical Industry" by the All-China Federation of Industry and Commerce (ACFIC), Pharmaceutical Chamber of Commerce has become one of the authoritative lists of Chinese pharmaceutical industry. The ACFIC invited first-class Chinese experts to form a selection team. The selection adheres to the principles of open collection, objective data, strict screening, and fair selection. United with a number of well…
Cambridge, UK: Following the resounding success of the inaugural edition of the tech Kickstarter Competition in Jan 2023, o2h technology (a business vertical of the o2h group) is excite to launch the second edition of the o2h tech kickstarter competition designed to support seed stage life science, greentech, and tech/AI companies with their MVP, web, mobile app design & development needs.
The first edition of this competition received an overwhelming response. We had over 25 seed early-stage companies who applied, out of which we chose 3 final winners including …
Following the resounding success of its inaugural edition in Jan 2023, o2h technology (a business vertical of the o2h group) is excited to launch the second edition of the o2h tech kickstarter competition designed to support seed stage life science, greentech, and tech/AI companies with their MVP, web, mobile app design & development needs.
The first edition of this competition received an overwhelming response. We had over 25 seed early-stage companies who applied, out of which we chose 3 final winners including RouteZero, a Greentech startup committed to decarbonising business travel,…